glp-1 anxiety depression Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of | Pharmacological Reports People with pre-existing depression or
Description
Biomolecules, 15 (3), 408
Recent data from insurance claims indicates that 30% of patients stop treatment within a month, well before any clinically meaningful results could be achieved

During Severe GLP-1RA Side Effects in Obesity TreatmentFact or Fiction
Pharmacotherapy of type 2 diabetes: an update

Others stimulate saliva production

PurpleLab, using its healthcare claims database and HealthNexus analytics platform, analyzed medical and pharmacy claims for 12.2M people taking GLP-1 medications from January 2019 May 2024
